Amino Acid Cocktail Supercharges LNP Delivery for mRNA and CRISPR Therapies
**By Curie | Biotech Reporter** March 13, 2026 — The lipid nanoparticles (LNPs) that delivered COVID-19 vaccines to billions of people are showing promise for a much broader set of therapies — if only they could get inside cells more efficiently.
By Curie | Biotech Reporter
March 13, 2026 — The lipid nanoparticles (LNPs) that delivered COVID-19 vaccines to billions of people are showing promise for a much broader set of therapies — if only they could get inside cells more efficiently. Now, researchers at Biohub have found a surprisingly simple solution: add a few common amino acids.
In a study published in Science Translational Medicine, the team reports that co-injecting three amino acids — methionine, arginine, and serine — alongside LNPs dramatically improves delivery of both mRNA and CRISPR gene-editing payloads. The approach produced a 5- to 20-fold increase in mRNA expression across multiple cell types and administration routes, and boosted CRISPR editing efficiency from roughly 25% to nearly 90% in a single dose.
"Gene editing and mRNA-based therapies will play increasing roles in the medicine of the future, but they require LNPs to reach and enter cells," said Shana O. Kelley, PhD, president of bioengineering at Biohub. "Any LNP formulation being developed today could potentially benefit from our approach."
The problem the researchers solved: LNPs work far better in lab dishes than in living organisms. Most of the field has focused on redesigning the nanoparticles themselves. But the Biohub team asked whether the body's metabolic environment might be the real bottleneck.
Standard cell culture media contain nutrient concentrations far higher than cells experience in the bloodstream. When the team grew cells in a plasma-like medium mimicking the body's conditions, LNP uptake dropped by 50-80%. The culprit: suppressed amino acid metabolic pathways in cells operating in the leaner in vivo environment.
The fix was straightforward. In mouse experiments, LNPs carrying growth hormone mRNA for acetaminophen-induced liver injury produced just 33% survival. Adding the amino acid cocktail pushed survival to 100%. In lung-targeted CRISPR editing, standard delivery achieved 20-30% gene modification — typical for the approach. With the amino acid supplement, editing reached 85-90% after a single dose — levels approaching what's needed for diseases like cystic fibrosis.
The cocktail works by enhancing a clathrin-independent, carrier-mediated endocytic pathway, essentially widening the door through which nanoparticles enter cells.
